Impact of recurrence score assay varies with patient age

(HealthDay)—For women with early-stage breast cancer, the impact of receipt of the 21-gene recurrence score (RS) assay varies with patient age, according to a study published online Nov. 23 in the Journal of Clinical Oncology.

5 hours ago
popularity1 comments 0

Promising drug combination for advanced prostate cancer

A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals ...

10 hours ago
popularity6 comments 0

Scientists identify promising new melanoma drug

A new drug discovered by scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) may show promise for treating skin cancers that are resistant or unresponsive to today's leading therapies.

10 hours ago
popularity4 comments 0

Portrazza approved for advanced lung cancer

(HealthDay)—Portrazza (necitumumab), in combination with two other chemotherapy drugs, has been approved by the U.S. Food and Drug Administration to treat advanced squamous non-small cell lung cancer, the agency said Tuesday ...

16 hours ago
popularity2 comments 0

Instrument assesses competency in detecting melanoma

(HealthDay)—The Skin Cancer Objective Structured Clinical Examination is a well-developed instrument that can assess medical student competency in detecting melanoma, according to research published in the December issue ...

Nov 24, 2015
popularity0 comments 0